Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 17/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 15/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3174760 | 0.79 | SLC6A4 (0.45) | SLC6A2SLC6A4SLC6A3TSHR | |
| SCHEMBL2092663 | 0.75 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3RAB9A | |
| SCHEMBL1830085 | 0.74 | HRH1 (0.41) | SLC6A2SLC6A4SLC6A3TSHRRAB9A | |
| SCHEMBL11539838 | 0.72 | MEN1 (0.42) | SLC6A2SLC6A4SLC6A3MEN1RAB9A | |
| SCHEMBL13696497 | 0.72 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3KMT2AALDH1A1 | |
| SCHEMBL7701922 | 0.72 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL2088693 | 0.71 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3MEN1NPC1 | |
| SCHEMBL10035281 | 0.71 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3ALDH1A1GLA | |
| SCHEMBL3554168 | 0.71 | SCD (0.41) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL10525480 | 0.71 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741934-B2 | Inhibitors of ion channels | PFIZER LIMITED (GB) | 2014-06-03 | — | — | US | disclosed |
| US-20130072471-A1 | Inhibitors of Ion Channels | MARRON BRIAN EDWARD (US) | 2013-03-21 | — | — | US | disclosed |
| US-8357711-B2 | Heterocyclic sulfonamides as inhibitors of ion channels | PFIZER LIMITED (GB) | 2013-01-22 | — | — | US | disclosed |
| EP-1995241-B1 | Inhibitors of ion channels | ICAGEN INC (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| EP-1995241-A1 | Inhibitors of ion channels | ICAgen, Incorporated (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2008118758-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (GB) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072471-A1 | Inhibitors of Ion Channels | TRPV1, TRPV5, TRPA1 | SLC6A2 218/4885SLC6A4 207/4885SLC6A3 248/4885 |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | SLC6A2 218/4885SLC6A4 207/4885SLC6A3 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.